These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

152 related articles for article (PubMed ID: 35532260)

  • 21. Engineering Introns to Express RNA Guides for Cas9- and Cpf1-Mediated Multiplex Genome Editing.
    Ding D; Chen K; Chen Y; Li H; Xie K
    Mol Plant; 2018 Apr; 11(4):542-552. PubMed ID: 29462720
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Get ready for the CRISPR/Cas system: A beginner's guide to the engineering and design of guide RNAs.
    Ma S; Lv J; Feng Z; Rong Z; Lin Y
    J Gene Med; 2021 Nov; 23(11):e3377. PubMed ID: 34270141
    [TBL] [Abstract][Full Text] [Related]  

  • 23. New vectors for simple and streamlined CRISPR-Cas9 genome editing in Saccharomyces cerevisiae.
    Laughery MF; Hunter T; Brown A; Hoopes J; Ostbye T; Shumaker T; Wyrick JJ
    Yeast; 2015 Dec; 32(12):711-20. PubMed ID: 26305040
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Gene editing in mouse zygotes using the CRISPR/Cas9 system.
    Wefers B; Bashir S; Rossius J; Wurst W; Kühn R
    Methods; 2017 May; 121-122():55-67. PubMed ID: 28263886
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Precision genome editing in the CRISPR era.
    Salsman J; Dellaire G
    Biochem Cell Biol; 2017 Apr; 95(2):187-201. PubMed ID: 28177771
    [TBL] [Abstract][Full Text] [Related]  

  • 26. [CRISPR/CAS9, the King of Genome Editing Tools].
    Bannikov AV; Lavrov AV
    Mol Biol (Mosk); 2017; 51(4):582-594. PubMed ID: 28900076
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Versatility of chemically synthesized guide RNAs for CRISPR-Cas9 genome editing.
    Kelley ML; Strezoska Ž; He K; Vermeulen A; Smith Av
    J Biotechnol; 2016 Sep; 233():74-83. PubMed ID: 27374403
    [TBL] [Abstract][Full Text] [Related]  

  • 28. CRISPR GUARD protects off-target sites from Cas9 nuclease activity using short guide RNAs.
    Coelho MA; De Braekeleer E; Firth M; Bista M; Lukasiak S; Cuomo ME; Taylor BJM
    Nat Commun; 2020 Aug; 11(1):4132. PubMed ID: 32807781
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Optimization of genome editing through CRISPR-Cas9 engineering.
    Zhang JH; Adikaram P; Pandey M; Genis A; Simonds WF
    Bioengineered; 2016 Apr; 7(3):166-74. PubMed ID: 27340770
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Efficient Mutagenesis of Marek's Disease Virus-Encoded microRNAs Using a CRISPR/Cas9-Based Gene Editing System.
    Luo J; Teng M; Zai X; Tang N; Zhang Y; Mandviwala A; Reddy VRAP; Baigent S; Yao Y; Nair V
    Viruses; 2020 Apr; 12(4):. PubMed ID: 32325942
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Minimal 2'-O-methyl phosphorothioate linkage modification pattern of synthetic guide RNAs for increased stability and efficient CRISPR-Cas9 gene editing avoiding cellular toxicity.
    Basila M; Kelley ML; Smith AVB
    PLoS One; 2017; 12(11):e0188593. PubMed ID: 29176845
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Method for Dual Viral Vector Mediated CRISPR-Cas9 Gene Disruption in Primary Human Endothelial Cells.
    Gong H; Liu M; Klomp J; Merrill BJ; Rehman J; Malik AB
    Sci Rep; 2017 Feb; 7():42127. PubMed ID: 28198371
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Platforms of in vivo genome editing with inducible Cas9 for advanced cancer modeling.
    Jo N; Sogabe Y; Yamada Y; Ukai T; Kagawa H; Mitsunaga K; Woltjen K; Yamada Y
    Cancer Sci; 2019 Mar; 110(3):926-938. PubMed ID: 30588718
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Cell-type-specific genome editing with a microRNA-responsive CRISPR-Cas9 switch.
    Hirosawa M; Fujita Y; Parr CJC; Hayashi K; Kashida S; Hotta A; Woltjen K; Saito H
    Nucleic Acids Res; 2017 Jul; 45(13):e118. PubMed ID: 28525578
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Gene Editing in Human Induced Pluripotent Stem Cells Using Doxycycline-Inducible CRISPR-Cas9 System.
    Thamodaran V; Rani S; Velayudhan SR
    Methods Mol Biol; 2022; 2454():755-773. PubMed ID: 33830454
    [TBL] [Abstract][Full Text] [Related]  

  • 36. CRISPR-Cas9 Genome Editing in Human Cell Lines with Donor Vector Made by Gibson Assembly.
    Sahoo N; Cuello V; Udawant S; Litif C; Mustard JA; Keniry M
    Methods Mol Biol; 2020; 2115():365-383. PubMed ID: 32006411
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Identification of RNA Binding Partners of CRISPR-Cas Proteins in Prokaryotes Using RIP-Seq.
    Sharma S; Sharma CM
    Methods Mol Biol; 2022; 2404():111-133. PubMed ID: 34694606
    [TBL] [Abstract][Full Text] [Related]  

  • 38. RGEN Editing of RNA and DNA: The Long and Winding Road from Catalytic RNAs to CRISPR to the Clinic.
    Sullenger BA
    Cell; 2020 May; 181(5):955-960. PubMed ID: 32470403
    [TBL] [Abstract][Full Text] [Related]  

  • 39. An Era of CRISPR/ Cas9 Mediated Plant Genome Editing.
    Khurshid H; Jan SA; Shinwari ZK; Jamal M; Shah SH
    Curr Issues Mol Biol; 2018; 26():47-54. PubMed ID: 28879855
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Targeting miRNA by CRISPR/Cas in cancer: advantages and challenges.
    Hussen BM; Rasul MF; Abdullah SR; Hidayat HJ; Faraj GSH; Ali FA; Salihi A; Baniahmad A; Ghafouri-Fard S; Rahman M; Glassy MC; Branicki W; Taheri M
    Mil Med Res; 2023 Jul; 10(1):32. PubMed ID: 37460924
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.